73604-36-1

Upstream product

• 2018-66-8 Z-Leu-OH 
• 10342-47-9 L-valine-L-phenylalanine methyl ester hydrochloride 

Downstream Products

• 73604-37-2 Leu-Val-Phe-OCH₃*HCl 
• 24210-21-7 Z-Leu-Leu-Val-Phe-OCH₃ 
• 73604-34-9 L-2-hydroxy-3-phenylpropanoyl-Leu-Val-Phe-OCH₃ 
• 24210-22-8 Leu-Leu-Val-Phe-OMe hydrochloride 
• 73604-33-8 D-α-Hydroxyisovaleryl-Leu-Val-Phe-OCH3 
• 73604-33-8 L-α-hydroxyisovaleryl-Leu-Val-Phe-OCH3 
• 73604-32-7 D-α-hydroxyisocaproyl-Leu-Val-Phe-OCH3 
• 73604-32-7 L-α-hydroxyisocaproyl-Leu-Val-Phe-OCH3 
• 73604-35-0 D-α-hydroxyphenylacetyl-Leu-Val-Phe-OCH3 
• 73604-35-0 L-α-hydroxyphenylacetyl-Leu-Val-Phe-OCH3 

Relevant academic research and scientific papers

N-(α-Hydroxyalkanoyl) Derivatives of Leu-Val-Phe-OCH3 as Inhibitors of Renin

The following N-(α-hydroxyalkanoyl) derivatives of Leu-Val-Phe-OCH3 were synthesized and tested for their ability to inhibit human amniotic renin: D- and L-α-hydroxyisocaproyl-Leu-Val-Phe-OCH3, D- and L-α-hydroxyisovaleryl-Leu-Val-Phe-OCH3, L-2-hydroxy-3-phenylpropanoyl-Leu-Val-Phe-OCH3, and D- and L-α-hydroxyphenylacetyl-Leu-Val-Phe-OCH3.Analysis of the compounds through the use of Dixon plots showed all of the compounds to be competitive inhibitors of renin.All but D-α-hydroxyisovaleryl-Leu-Val-Phe-OCH3 were found to be more active than the known tetrapeptideinhibitor Leu-Leu-Val-Phe-OCH3 (1).The two most active compounds of the series were L-α-hydroxyisocaproyl-Leu-Val-Phe-OCH3 (Ki = 0.23 mM) and L-α-hydroxyisovaleryl-Leu-Val-Phe-OCH3 (Ki = 0.3 mM).